An 18.3% upside forecast for the total U.S. stock market hinges on micro bets in obscure biotech and distilling stocks

An 18.3% upside forecast for the total U.S. stock market is only as strong as the obscure biotech and distilling stocks underpinning it. The Vanguard Total Stock Market ETF (VTI), with $587.54 billion in assets and 3,466 holdings, rose 0.067% in pre-market trading on April 15, 2026. Its year-to-date gain stands at 1.33%, with a 5.56% rise over the past five days. The ETF is rated a Moderate Buy by TipRanks’ analyst consensus, which aggregates weighted ratings on its underlying holdings. The average price target of $405.45 implies that upside. But that forecast does not rest on Apple, Microsoft, or even Nvidia. It is pulled upward by stocks like FiscalNote Holdings (NOTE), Sangamo Therapeutics (SGMO), Reviva Pharmaceuticals Holdings (RVPH), Curis Inc. (CRIS), and Heritage Distilling Holding Company (IPST)—five names among 3,466, each carrying negligible weight in the portfolio. The same market proxy that gives investors exposure to the full breadth of U.S. equities now has its forward outlook shaped by micro positions in unproven companies. VTI’s Smart Score of seven suggests performance in line with the broader market. The irony is that the ‘broader market’ it tracks may be moving in a direction set by its smallest, most speculative corners.